Dyne Therapeutics (DYN) Profit After Tax (2019 - 2026)
Dyne Therapeutics (DYN) recorded quarterly Profit After Tax of -$120.9 million in Q1 2026, down 7.95% quarter-over-quarter from -$112.0 million in Q4 2025, and down 4.76% on a YoY basis from -$126.9 million in Q1 2025.
Dyne Therapeutics (DYN) Profit After Tax (2019 - 2026) Analysis & Trends
Dyne Therapeutics' Profit After Tax history runs 8 years deep, the most recent figure standing at -$120.9 million for Q1 2026.
- In Q1 2026, Profit After Tax fell 4.76% year-over-year to -$120.9 million; the TTM figure through Mar 2026 stood at -$451.7 million (down 23.04% YoY), while the FY2025 annual figure was -$446.2 million, down 40.58% from the prior year.
- Profit After Tax was -$120.9 million for Q1 2026 at Dyne Therapeutics, down from -$112.0 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of -$35.6 million in Q1 2022 to a low of -$120.9 million in Q1 2026.
- Historically, Profit After Tax has averaged -$75.8 million across 5 years, with a median of -$65.6 million in 2024.
- The sharpest annual moves came in 2022 and 2025: Profit After Tax gained 25.02% in 2022, then tumbled 75.72% in 2025.
- A 5-year view of Profit After Tax shows it stood at -$38.8 million in 2022, then tumbled by 71.63% to -$66.6 million in 2023, then tumbled by 34.37% to -$89.5 million in 2024, then retreated by 25.03% to -$112.0 million in 2025, then slipped by 7.95% to -$120.9 million in 2026.
- The last three Profit After Tax figures came in at -$120.9 million (Q1 2026), -$112.0 million (Q4 2025), and -$108.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 30.90 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | -3.63 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -753,254.00 |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -56.74 Mn |
| 10 | Dyne Therapeutics | 3.00 Bn | 3.00 Bn | - | -120.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -120.85 Mn |
| Dec 31, 2025 | -111.96 Mn |
| Sep 30, 2025 | -108.04 Mn |
| Jun 30, 2025 | -110.86 Mn |
| Mar 31, 2025 | -115.36 Mn |
| Dec 31, 2024 | -89.54 Mn |
| Sep 30, 2024 | -97.13 Mn |
| Jun 30, 2024 | -65.10 Mn |
| Mar 31, 2024 | -65.65 Mn |
| Dec 31, 2023 | -66.64 Mn |
| Sep 30, 2023 | -60.21 Mn |
| Jun 30, 2023 | -64.90 Mn |
| Mar 31, 2023 | -44.19 Mn |
| Dec 31, 2022 | -38.83 Mn |
| Sep 30, 2022 | -41.39 Mn |
| Jun 30, 2022 | -52.30 Mn |
| Mar 31, 2022 | -35.58 Mn |
| Dec 31, 2021 | -51.79 Mn |
| Sep 30, 2021 | -42.58 Mn |
| Jun 30, 2021 | -29.96 Mn |